2 results
Approved WMOWill not start
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
Approved WMORecruiting
The present study is aimed at identifying the specific routes of plitidepsin excretion and elimination following its administration to patients with advanced tumors. Also, the study design may allow the identification and quantification, if possible…